Comparison of glycaemic control and cardiovascular risk profile in patients with type 2 diabetes during treatment with either repaglinide or metformin

Giuseppe Derosa, Amedeo Mugellini, Leonardina Ciccarelli, Giuseppe Crescenzi, Roberto Fogari

Research output: Contribution to journalArticle

Abstract

Objective: To compare glycaemic control and cardiovascular risk profile in patients with type 2 diabetes following 12 months' treatment with either repaglinide or metformin. Study design and methods: This was an open uncontrolled randomised study in n=112 patients with inadequately controlled type 2 diabetes not previously treated with oral hypoglycaemic agents. Patients beginning treatment with either repaglinide or metformin entered an 8-week titration period (to optimise dosage: repaglinide, 2-4 mg/day; metformin, 1500-2500 mg/day) followed by a 12-month treatment period. Glycaemic control and cardiovascular risk factors were determined at baseline and at the end of the treatment period. Results: Mean (S.D.) final drug doses were 3 (±1) mg/day in the repaglinide group and 2000 (±500) mg/day in the metformin group. Significant improvements in glycaemic control [glycated haemoglobin, fasting and 2-h postprandial plasma glucose (PPG)] were demonstrated in both treatment groups. The decrease in PPG was significantly greater in the repaglinide group (P

Original languageEnglish
Pages (from-to)161-169
Number of pages9
JournalDiabetes Research and Clinical Practice
Volume60
Issue number3
DOIs
Publication statusPublished - Jun 1 2003

Keywords

  • Cardiovascular risk
  • Glycaemic control
  • Metformin
  • Repaglinide
  • Type 2 diabetes mellitus

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Fingerprint Dive into the research topics of 'Comparison of glycaemic control and cardiovascular risk profile in patients with type 2 diabetes during treatment with either repaglinide or metformin'. Together they form a unique fingerprint.

  • Cite this